The stock of Shire PLC (LON:SHP) is a huge mover today! The stock increased 3.27% or GBX 160.03 on November 10, hitting GBX 5057.03. About 5.03M shares traded hands or 104.47% up from the average. Shire PLC (LON:SHP) has risen 15.41% since April 12, 2016 and is uptrending. It has outperformed by 9.77% the S&P500.
The move comes after 9 months positive chart setup for the GBX 45.76 billion company. It was reported on Nov, 10 by Barchart.com. We have GBX 8495.81 PT which if reached, will make LON:SHP worth GBX 31.12B more.
Shire PLC (LON:SHP) Ratings Coverage
Out of 24 analysts covering Shire PLC (LON:SHP), 21 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 88% are positive. Shire PLC has been the topic of 224 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Bernstein maintained Shire PLC (LON:SHP) on Monday, November 23 with “Outperform” rating. The stock of Shire PLC (LON:SHP) earned “Overweight” rating by JP Morgan on Wednesday, August 5. The rating was maintained by Liberum Capital on Thursday, July 14 with “Buy”. The rating was maintained by BNP Paribas on Tuesday, October 20 with “Neutral”. The stock of Shire PLC (LON:SHP) earned “Buy” rating by Citigroup on Friday, July 24. BNP Paribas maintained the shares of SHP in a report on Monday, March 14 with “Outperform” rating. BNP Paribas maintained Shire PLC (LON:SHP) rating on Tuesday, April 26. BNP Paribas has “Outperform” rating and GBX 5700 price target. BNP Paribas maintained it with “Outperform” rating and GBX 5900 target price in Thursday, August 18 report. The firm has “Buy” rating given on Tuesday, July 28 by Berenberg. The firm has “Outperform” rating by Bernstein given on Wednesday, January 13.
More news for Shire PLC (LON:SHP) were recently published by: Streetinsider.com, which released: “Shire plc (SHPG) Misses Q3 EPS by 4c” on November 01, 2016. Seekingalpha.com‘s article titled: “Shire Plc (SHPG) Q3 2016 Results – Earnings Call Transcript” and published on November 01, 2016 is yet another important article.
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The company has a market cap of 45.76 billion GBP. The Firm operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It has a 70.66 P/E ratio.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.